600436.SH
片仔癀
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 123.76
−0.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.6B | 9.0B | 10.8B | 10.1B | 8.7B |
| Cost of Revenue | 5.6B | 5.7B | 6.2B | 5.4B | 4.7B |
| Gross Profit | 3.0B | 3.3B | 4.6B | 4.7B | 4.0B |
| Operating Expenses | |||||
| R&D Expense | 268.9M | 252.2M | 269.6M | 232.4M | 230.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 375.3M | 359.2M | 340.5M | 367.0M | 331.0M |
| Selling & Marketing Expense | 435.1M | 401.0M | 517.6M | 782.8M | 483.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.2B | 1.1B | 1.2B | 1.5B | 1.1B |
| Cost and Expenses | 6.7B | 6.8B | 7.4B | 6.8B | 5.8B |
| Operating Income (EBIT) | 2.2B | 2.5B | 3.6B | 3.4B | 3.0B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 2.2B | 2.5B | 3.5B | 3.4B | 3.0B |
| Income Tax Expense | 361.3M | 394.5M | 543.2M | 517.8M | 454.8M |
| Bottom Line | |||||
| Net Income | 1.9B | 2.2B | 3.0B | 2.8B | 2.5B |
| Earnings from Cont. Ops | 1.9B | 2.1B | 3.0B | 2.9B | 2.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.9B | 2.2B | 3.0B | 2.8B | 2.5B |
| Per Share | |||||
| Basic EPS | CN¥3.15 | CN¥3.58 | CN¥4.93 | CN¥4.64 | CN¥4.10 |
| Diluted EPS | CN¥3.15 | CN¥3.58 | CN¥4.93 | CN¥4.64 | CN¥4.10 |
| Revenue Per Share | CN¥14.23 | CN¥14.93 | CN¥17.87 | CN¥16.68 | CN¥14.42 |
| Shares | |||||
| Basic Shares Outstanding | 604.5M | 603.0M | 603.9M | 602.9M | 603.0M |
| Diluted Shares Outstanding | 604.5M | 603.0M | 603.9M | 602.9M | 603.0M |
| Profitability Metrics | |||||
| EBITDA | — | 2.6B | 3.6B | 3.5B | 3.0B |
| D&A | — | 88.5M | 64.9M | 94.1M | 62.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026